Replies to post #310442 on Avid Bioservices Inc (CDMO)

[biopharm]

'We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer,' FDA Commissioner Scott Gottlieb said in a news release. 'New technologies such as gene and cell therapies hold out the potential to transform medicine.'

"The Enlightenment Age of Disease" sounds better and now since this new treatment was pioneered at Penn (one of Parker Cancer Institute members as with Carl June..), my question is would patents evolving out from knowledge that would not be evident or even plausible via PS Targeting, how does Peregrine Pharmaceuticals handle such possibilities?

Peregrine can have undisclosed collaboration with x parties and now these x parties NOW understand what protein pathways become important and possibly PS Targeting allows for this....

"Each patient's immune system T cells are removed, programmed to attack acute lymphoblastic leukemia cells, then returned to the patient. "

....or they are already well aware and just making me think harder than I need to, all so PS Targeting assisted CART cell approvals can be approved ahead of the competition

Gilead....Kite....Juno....MSK.....Heat .....Intellia ....

PS: if this does turn out for a record week for naked short shares, what do we follow?? The money....the science....the yellow brick road....or the puzzle pieces